ArticleJournal of thoracic disease2026
Association between albumin-bilirubin score and all-cause mortality in patients with acute respiratory failure: a cohort study based on the MIMIC-IV database.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The albumin-bilirubin (ALBI) score represents a novel indicator integrating liver function and nutritional status. Its prognostic value has been demonstrated in a variety of diseases, but its prognostic significance in individuals with acute respiratory failure (ARF) is still elusive. This research aimed to discern the association between ALBI score and short-term all-cause mortality (ACM) in individuals with ARF admitted to the intensive care unit (ICU). Methods: This was a retrospective cohort study. Data were acquired from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Totally, 6,285 individuals with ARF were included in this study. These individuals were classified into four groups as per the quartile of the ALBI score. The primary outcome was the 30-day ACM rate, and the secondary outcome was the 90-day ACM rate. Kaplan-Meier (KM) curves were used to compare survival rates among the cohorts. The association between ALBI score and ACM rates was explored using a multivariate Cox proportional hazards regression model and restricted cubic spline (RCS) analysis. The area under the receiver operating characteristic (ROC) curve (AUC) was calculated, and the incremental predictive value of ALBI was evaluated by the integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Results: Among the 6,285 participants, the median age was 65.92 years, and 56.66% were male. KM analysis implied that a higher ALBI score was significantly associated with reduced 30- and 90-day survival rates (log-rank test P<0.001). Multivariate Cox regression analysis suggested that compared with the lowest quartile (Q1), individuals with the highest ALBI score (Q4) had a 44.6% elevated risk of 30-day ACM [hazard ratio (HR): 1.446; 95% confidence interval (CI): 1.208 to 1.731] and a 58.0% elevated risk of 90-day ACM (HR: 1.580; 95% CI: 1.347 to 1.853). RCS analysis further implied a linear positive association between ALBI score and the risk of ACM. Furthermore, incorporating ALBI score into the Sequential Organ Failure Assessment (SOFA) and Oxford Acute Severity of Illness Score (OASIS) scoring systems improved the model's predictive accuracy. Conclusions: In individuals with ARF in the ICU, a higher ALBI score at admission is independently associated with a significantly elevated risk of 30- and 90-day ACM. The ALBI score may serve as a useful adjunctive tool for risk stratification, but its clinical utility needs to be corroborated in prospective and external validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.